SGK
BHC icon

Steigerwald Gordon & Koch’s Bausch Health BHC Stock Holding History

Steigerwald Gordon & Koch’s Portfolio BHC Stock Details BHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-346,842
Closed -$7.92M – 110
2022
Q1 		$7.92M Buy
+346,842
New +$8.48M 1.21% 37

Other funds holding BHC

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Steigerwald Gordon & Koch's BHC Position: Q2 2022 in Review

Steigerwald Gordon & Koch sold out of Bausch Health (BHC) in Q2 2022, closing a stake of 346,842 shares — an estimated $7.92M sold.

Steigerwald Gordon & Koch first reported a position in BHC in Q1 2022 and held it in 1 quarter. The position peaked at $7.92M in Q1 2022. 327 funds tracked by Wall St. Rank hold BHC as of Q2 2022.

  • Steigerwald Gordon & Koch reported no remaining Bausch Health position as of Q2 2022 after selling out during the quarter.
  • Steigerwald Gordon & Koch sold 346,842 Bausch Health shares in Q2 2022, an estimated $7.92M.
  • Steigerwald Gordon & Koch first reported a position in Bausch Health in Q1 2022 and held it in 1 quarter.
  • Steigerwald Gordon & Koch's Bausch Health position peaked at $7.92M in Q1 2022.
  • 327 funds tracked by Wall St. Rank held Bausch Health as of Q2 2022.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2022, filed 14 Jul 2022.